different lots of plasma.

Supervisor: Reviews analytical data and ensures matrix effect is within acceptable limits.

QA Officer: Verifies documentation, reviews calculations, and ensures compliance with ICH M10 and FDA guidelines.

4. Accountability

The Head of Bioanalytical Department is accountable for ensuring matrix effect assessments are conducted accurately and reported as part of method validation documentation.

5. Procedure

5.1 Selection of Plasma Lots

1. Obtain blank plasma from at least six independent sources, including:
   • 4 normal human plasma lots
   • 1 hemolyzed plasma lot
   • 1 lipemic plasma lot
2. Label and record plasma lot IDs in Annexure-1: Plasma Lot Record Sheet.

5.2 Sample Preparation

1. Prepare two sets of samples for each matrix lot:
   • Post-extraction blank (without analyte)
   • Post-extraction spiked at LQC and HQC levels
2. Prepare corresponding neat standard samples at equivalent concentrations in mobile phase or reconstitution solution.

5.3 Instrumental Analysis

1. Inject matrix-spiked and neat standard samples using a validated LC-MS/MS method.
2. Ensure acceptable system suitability before injecting test samples.
3. Record area responses of analyte and internal standard (IS) for each sample.

5.4 Data Evaluation

1. Calculate Matrix Factor (MF) for each lot as follows:
   • MF = Peak Area in Matrix / Peak Area in Neat Solution
2. Calculate IS-normalized MF for each lot:
   • IS-Normalized MF = MF of Analyte / MF of IS
3. Compute %CV of IS-normalized MF across all lots.

5.5 Acceptance Criteria

1. %CV of IS-normalized MF should be ≤15% at both LQC and HQC levels.
2. Matrix effects are considered negligible if all MFs are within ±15% variation compared to neat standard.
3. Record results in Annexure-2: Matrix Effect Summary.

5.6 Documentation and Reporting

1. Include chromatograms, calculation sheets, MF results, %CV, and acceptance evaluation.
2. Prepare matrix effect assessment report and submit to QA for approval.
3. Include matrix effect report in method validation dossier for regulatory submission.

6. Abbreviations

• BA/BE: Bioavailability/Bioequivalence
• MF: Matrix Factor
• %CV: Percent Coefficient of Variation
• LQC: Low Quality Control
• HQC: High Quality Control
• IS: Internal Standard

7. Documents

1. Plasma Lot Record Sheet – Annexure-1
2. Matrix Effect Summary – Annexure-2

8. References

• ICH M10: Bioanalytical Method Validation
• US FDA Guidance for Industry: Bioanalytical Method Validation (2022)
• Internal Method Validation Protocol

9. SOP Version

Version: 2.0

10. Approval Section

	Prepared By	Checked By	Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Plasma Lot Record Sheet

Plasma Lot ID	Type	Source	Date Received	Stored By
PL-LT-01	Normal	Blood Bank A	10/04/2025	Sunita Reddy
PL-LT-06	Lipemic	Clinical Lab B	12/04/2025	Rajesh Kumar

Annexure-2: Matrix Effect Summary

QC Level	Lot ID	MF Analyte	MF IS	IS-Normalized MF	%CV	Status
LQC	PL-LT-01	0.88	0.90	0.978	5.3	Accepted
HQC	PL-LT-02	1.02	1.00	1.020	4.1	Accepted

Revision History:

Revision Date	Revision No.	Details	Reason	Approved By
01/01/2022	1.0	Initial issue	New SOP	QA Head
17/04/2025	2.0	Added normalized MF calculation and annexures	ICH M10 Alignment	QA Head